Approach for Treatment of Cancer via Immunomodulation by Using Talabostat
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,564,986 | Approach for Treatment of Cancer via Immunomodulation by Using Talabostat In force · High confidence | Onkosxcel Therapeutics, LLC | In force | High confidence | ||
| Application 18/069,489 | Approach for Treatment of Cancer via Immunomodulation by Using Talabostat Abandoned Abandoned Oct 16, 2024 | Jazz Pharmaceuticals Ireland Limited | Abandoned | Abandoned Oct 16, 2024 | ||
| Application 18/802,908 | Novel Approach for Treatment of Cancer Using Immunomodulation Pending Not granted | OnkosXcel Therapeutics, LLC | Pending | Not granted |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Onkosxcel Therapeutics, LLC.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.